BASIC PHARMACOKINETICS AND PHARMACODYNAMICS

An Integrated Textbook and Computer Simulations

SARA ROSENBAUM



CONTENTS

Pi	etace		XVII
1	Intr	oduction to Pharmacokinetics and Pharmacodynamics	1
	1.1	Introduction: Drugs and Doses, 1	
	1.2	Introduction to Pharmacodynamics, 3	
		1.2.1 Drug Effects at the Site of Action, 3	
		1.2.2 Agonists, Antagonists, and Concentration–Response	
		Relationships, 6	
	1.3	Introduction to Pharmacokinetics, 9	
		1.3.1 Plasma Concentration of Drugs, 10	
		1.3.2 Processes in Pharmacokinetics, 11	
	1.4	Dose–Response Relationships, 13	
	1.5	Therapeutic Range, 14	
		1.5.1 Determination of the Therapeutic Range, 16	
	1.6	Summary, 18	
2	Pass	age of Drugs Through Membranes	20
	2.1	Introduction, 20	
	2.2	Structure and Properties of Membranes, 21	
	2.3	Passive Diffusion, 22	
		2.3.1 Transcellular Passive Diffusion, 24	
		2.3.2 Paracellular Passive Diffusion, 26	
	2.4	Carrier-Mediated Processes: Transport Proteins, 27	
		2.4.1 Uptake Transporters: SLC Superfamily, 28	
		2.4.2 Efflux Transporters: ABC Superfamily, 29	
		2.4.3 Characteristics of Transporter Systems, 31	

2.4.4 Simulation Exercise, 32

		2.4.5	Clinical Examples of Transporter Involvement in Drug Response, 33	
3	Drue	a Admi	inistration, Absorption, and Bioavailability	36
J				
	3.1		uction: Local and Systemic Drug Administration, 37	
	3.2		non Routes of Systemic Drug Administration, 37 Intravascular Direct Systemic Administration, 37	
		3.2.1	Extravascular Parenteral Routes, 38	
			Other Extravascular Routes, 38	
	2 2			
	3.3		riew of Oral Absorption, 40 t of Drug Absorption, 41	
	3.4	3.4.1	**	
			Individual Bioavailability Factors, 42	
	3.5		minants of the Bioavailability Factor, 43	
	5.5	3.5.1	•	
			Dissolution, 43	
		3.5.3	,	
			Adverse Events Within the Gastrointestinal Lumen, 44	
			Transcellular Passive Diffusion, 46	
			Paracellular Passive Diffusion, 47	
			Uptake and Efflux Transporters, 47	
			Presytemic Intestinal Metabolism or Extraction, 50	
		3.5.9	·	
	3.6		ors Controlling the Rate of Drug Absorption, 53	
		3.6.1	• •	
			Membrane Penetration—Controlled Absorption, 55	
		3.6.3		
	3.7		harmaceutics Classification System, 55	
	Pro	blems,		
		ference		
4	Dr	ug Dist	ribution	60
	4.1	Intro	duction, 61	
	4.2		nt of Drug Distribution, 61	
		4.2.1		
		4.2.2	,	
			Effects, 64	
		4.2.3		
			Volume of Distribution, 65	
		4.2.4	Plasma Protein Binding, 72	
	4.3		of Drug Distribution, 79	
		4.3.		
		4.3.2	Controlled Diag Distribution, 00	
	4.4		ribution of Drugs to the Central Nervous System, 83	
	Pre	oblems.	, 86	
		ference		

		C	ONIENIS	17
5	Dru	g Elimination and Clearance		88
	5.1	Introduction, 89		
	5.1	5.1.1 First-Order Elimination, 90		
		5.1.2 Determinants of the Elimination Rate Constant and the		
		Half-Life, 91		
	5.2	Clearance, 91		
		5.2.1 Definition and Determinants of Clearance, 91		
		5.2.2 Total Clearance, Renal Clearance, and Hepatic Clearance,	94	
		5.2.3 Relationships Among Clearance, Volume of Distribution,		
		Elimination Rate Constant, and Half-Life, 95		
		5.2.4 Primary and Secondary Parameters, 96		
	5.3	Renal Clearance, 97		
		5.3.1 Glomerular Filtration, 97		
		5.3.2 Tubular Secretion, 98		
		5.3.3 Tubular Reabsorption, 100		
		5.3.4 Putting Meaning into the Value of Renal Clearance, 101		
	5.4	Hepatic Clearance, 102		
		5.4.1 Phase I and Phase II Metabolism, 103		
		5.4.2 The Cytochrome P450 Enzyme System, 104		
		5.4.3 Glucuronidation, 105		
		5.4.4 Drug–Drug Interactions, 106		
		5.4.5 Hepatic Drug Transporters, 107		
		5.4.6 Kinetics of Drug Metabolism, 109		
		5.4.7 Hepatic Clearance, 111		
	5.5	Measurement of Clearances, 115		
		5.5.1 Total Body Clearance, 115		
		5.5.2 Renal Clearance, 117		
		5.5.3 Fraction of the Drug Excreted Unchanged, 120		
		plems, 121		
	Refe	erences, 124		
_	~			100
6		npartmental Models in Pharmacokinetics		126
		Introduction, 127		
	6.2	Expressions for Component Parts of the Dose–Plasma		
		Concentration Relationship, 127		
		6.2.1 Effective Dose, 127		
		6.2.2 Rate of Drug Absorption, 128		
		6.2.3 Rate of Drug Elimination, 129		
		6.2.4 Rate of Drug Distribution, 129		
	6.3	Putting Everything Together: Compartments and Models, 130		
		6.3.1 One-Compartment Model, 130		
		6.3.2 Two-Compartment Model, 131		
	<i>C A</i>	6.3.3 Three-Compartment Model, 131		
	6.4	Examples of Complete Compartment Models, 133		

6.4.1 Intravenous Bolus Injection in a One-Compartment Model

with First-Order Elimination, 133

•	\sim	NIT	$\Gamma F N$	רו	٦C

	6.5 6.6 Probl	6.4.2 Intravenous Bolus Injection in a Two-Compartment Model with First-Order Elimination, 134 6.4.3 First-Order Absorption in a Two-Compartment Model with First-Order Elimination, 135 Use of Compartmental Models to Study Metabolite Pharmacokinetics, 136 Selecting and Applying Models, 137 ems, 138 mmended Reading, 138	
,		macokinetics of an Intravenous Bolus Injection in a Compartment Model	139
		Introduction, 140	
		One-Compartment Model, 140	
		Pharmacokinetic Equations, 142	
		7.3.1 Basic Equation, 142	
		7.3.2 Half-Life, 143	
	7.4	7.3.3 Time to Eliminate a Dose, 143 Simulation Exercise, 144	
	7.5	·	
		7.5.1 Predicting Plasma Concentrations, 145	
		7.5.2 Duration of Action, 146	
		7.5.3 Value of a Dose to Give a Desired Initial Plasma	
		Concentration, 147 7.5.4 Intravenous Loading Dose, 147	
	7.6	Determination of Pharmacokinetic Parameters Experimentally, 148	
		7.6.1 Study Design for the Determination of Parameters, 149	
	~ ~	7.6.2 Pharmacokinetic Analysis, 149	
		Pharmacokinetic Analysis in Clinical Practice, 153 blems, 155	
		commended Reading, 157	
6	n.		
8	Tw	armacokinetics of an Intravenous Bolus Injection in a o-Compartment Model	158
	8.1	Introduction, 159	
	8.2	Tissue and Compartmental Distribution of a Drug, 159	
		8.2.1 Drug Distribution to the Tissues, 159	
	0 2	8.2.2 Compartmental Distribution of a Drug, 160	
	8.3	1	
		8.3.1 Distribution: A , α , and the Distribution $t_{1/2}$, 163 8.3.2 Elimination: B , β , and the Beta $t_{1/2}$, 163	
	8.4	Relationship Between Macro and Micro Rate Constants, 164	
	8.5	Primary Pharmacokinetic Parameters, 165	
		8.5.1 Clearance, 165	
		8.5.2 Distribution Clearance, 166	
	8.6	8.5.3 Volume of Distribution, 167	
	0.0	Simulation Exercise, 170	

8.7	Determination of the Pharmacokinetic Parameters of the	
	Two-Compartment Model, 173	
	8.7.1 Determination of Intercepts and Macro Rate Constants, 173	
	8.7.2 Determination of the Micro Rate Constants: k_{12} , k_{21} , and k_{10} , 175	
	8.7.3 Determination of the Primary Pharmacokinetic	
	Parameters, 175	
8.8	Clinical Application of the Two-Compartment Model, 176	
0.0	8.8.1 Measurement of the Elimination Half-Life in the	
	Postdistribution Phase, 176	
	8.8.2 Determination of the Loading Dose, 177	
	8.8.3 Evaluation of a Dose: Monitoring Plasma	
	Concentrations and Patient Response, 179	
Prol	olems, 180	
	ommended Reading, 181	
RCC	oniniciaca Reading, 161	
Phar	macokinetics of Extravascular Drug Administration	182
9.1	Introduction, 183	
9.2	Model for First-Order Absorption in a One-Compartment Model, 184	
	9.2.1 Model and Equations, 184	
	9.2.2 Determination of the Model Parameters, 186	
	9.2.3 Absorption Lag Time, 192	
	9.2.4 Flip-Flop Model and Sustained-Release Preparations, 192	
	9.2.5 Determinants of T_{max} and C_{max} , 194	
9.3	Bioavailability, 195	
	9.3.1 Bioavailability Parameters, 195	
	9.3.2 Absolute Bioavailability, 197	
	9.3.3 Relative Bioavailability, 198	
	9.3.4 Bioequivalence, 198	
	9.3.5 Example Bioavailability Analysis, 198	
9.4	•	
	olems, 199	
Rec	ommended Reading, 200	
Intro	duction to Noncompartmental Analysis	201
10.1	Introduction, 201	
10.2	Mean Residence Time, 202	
10.3	Determination of Other Important Pharmacokinetic Parameters, 205	
10.4	Different Routes of Administration, 207	
10.5	Application of Noncompartmental Analysis to Clinical Studies, 208	
	ems, 210	
Phar	macokinetics of Intravenous Infusion in a One-Compartment Model	212
	•	
11.1	Introduction, 213	
11.2	Model and Equations, 214	
	1.1.7.1. DANG FARIADUR. 7.19	

9

10

11

		11.2.2 Application of the Basic Equation, 216	
		11.2.2 Application of the Basic Equation, 216 11.2.3 Simulation Exercise: Part 1, 216	
	112	Steady-State Plasma Concentration, 217	
	11.3	11.3.1 Equation for Steady-State Plasma Concentrations, 217	
		11.3.1 Equation for Steady-State Flashia Concentrations, 217 11.3.2 Application of the Equation, 217	
		11.3.2 Application of the Equation, 217 11.3.3 Basic Formula Revisited, 218	
		11.3.4 Factors Controlling Steady-State Plasma Concentration, 218	
		11.3.5 Time to Steady State, 219 11.3.6 Simulation Exercise: Part 2, 220	
	11.4		
	11.4	Loading Dose, 221	
		11.4.1 Loading-Dose Equation, 221	
	115	11.4.2 Simulation Exercise: Part 3, 223	
	11.5	Termination of Infusion, 223	
		11.5.1 Equations for Termination Before and After	
		Steady State, 223	
	11.6	11.5.2 Simulation Exercise: Part 4, 224	
	11.6	Individualization of Dosing Regimens, 224	
		11.6.1 Initial Doses, 224	
	Drobi	11.6.2 Monitoring and Individualizing Therapy, 225	
	FIOU	lems, 227	
12	Mult	tiple Intravenous Bolus Injections in the One-Compartment Model	230
	12.1	Introduction, 231	
	12.2		
	12.3		
		12.3.1 Calculation of Dosing Interval to Give Specific	
		Steady-State Peaks and Troughs, 235	
	12.4		
		12.4.1 Principle of Superposition, 236	
		12.4.2 Equations That Apply Before Steady State, 236	
	12.5		
		12.5.1 Steady-State Equations, 238	
		12.5.2 Average Plasma Concentration at Steady State, 240	
		12.5.3 Fluctuation, 242	
		12.5.4 Accumulation, 243	
		12.5.5 Time to Reach Steady State, 244	
		12.5.6 Loading Dose, 245	
	12.6		
	12.6 12.7	210	
		Pharmacokinetic-Guided Dosing Regimen Design, 246 12.7.1 General Considerations for Selection of the Dosing Interval, 246	
		Pharmacokinetic-Guided Dosing Regimen Design, 246 12.7.1 General Considerations for Selection of the Dosing Interval, 246 12.7.2 Protocols for Pharmacokinetic-Guided	
	12.7	Pharmacokinetic-Guided Dosing Regimen Design, 246 12.7.1 General Considerations for Selection of the Dosing Interval, 246 12.7.2 Protocols for Pharmacokinetic-Guided Dosing Regimens, 247	
	12.7 12.8	Pharmacokinetic-Guided Dosing Regimen Design, 246 12.7.1 General Considerations for Selection of the Dosing Interval, 246 12.7.2 Protocols for Pharmacokinetic-Guided Dosing Regimens, 247 Simulation Exercise, 251	
	12.7 12.8 Prot	Pharmacokinetic-Guided Dosing Regimen Design, 246 12.7.1 General Considerations for Selection of the Dosing Interval, 246 12.7.2 Protocols for Pharmacokinetic-Guided Dosing Regimens, 247	

13	Mult	tiple Int	ermittent Infusions	254
	13.1	Introd	uction, 254	
	13.2	-	y-State Equations for Multiple Intermittent	
	12.2		ons, 256	
	13.3		exponential Decay During a Dosing Interval:	
			nination of Peaks, Troughs, and Elimination ife, 259	
			Determination of Half-Life, 259	
			Determination of Peaks and Troughs, 261	
	13.4		nination of the Volume of Distribution, 261	
	13.5		dualization of Dosing Regimens, 264	
	13.6		ation Exercise, 265	
		Proble	ms, 265	
14	Mult	iple Ora	al Doses	267
	14.1	Introdu	action, 267	
	14.2		r-State Equations, 268	
		14.2.1	Time to Peak Steady-State Plasma Concentration, 269	
			Maximum Steady-State Plasma Concentration, 270	
			Minimum Steady-State Plasma Concentration, 271	
			Average Steady-State Plasma Concentration, 271	
		14.2.5	Overall Effect of Absorption Parameters on a	
	143	Equation	Steady-State Dosing Interval, 272 ons Used Clinically to Individualize Oral Doses, 272	
	14.5	14.3.1	Protocol to Select an Appropriate Equation, 273	
	14.4		ation Exercise, 274	
	Refe	rences, 2		
15	Nonli	inear Ph	narmacokinetics	277
	15.1	Linear	Pharmacokinetics, 277	
			ear Processes in Absorption, Distribution, Metabolism,	
			mination, 280	
	15.3		acokinetics of Capacity-Limited Metabolism, 281	
			Kinetics of Enzymatic Processes, 282	
	15.4	15.3.2	Plasma Concentration–Time Profile, 283	
	15.4	•	oin, 284	
		15.4.1	Basic Equation for Steady State, 285 Estimation of Doses and Plasma Concentrations, 287	
			Influence of K_m and V_{max} and Factors That Affect	
		15.4.5	These Parameters, 289	
		15.4.4	Time to Eliminate the Drug, 290	
		15.4.5	Time to Reach Steady State, 291	
		15.4.6	Individualization of Doses of Phenytoin, 292	
	Probl	ems, 29	· · · · · · · · · · · · · · · · · · ·	
	Refer	ences, 2	296	

xiv	CON	ITENTS	
16		duction to Pharmacodynamic Models and Integrated nacokinetic-Pharmacodynamic Models	297
		Introduction, 298	
	16.2	Classic Pharmacodynamic Models Based on Traditional	
		Receptor Theory, 299	
		16.2.1 Receptor Binding, 300	
		16.2.2 Response–Concentration Models, 302	
	16.3		
		16.3.1 Sigmoidal E_{max} and E_{max} Models, 308 16.3.2 Linear Adaptations of the E_{max} Model, 310	
	16.4		
	10.4	a PK Model for Intravenous Bolus Injection in a	
		One-Compartment Model, 312	
		16.4.1 Simulation Exercise, 314	
	16.5	Hysteresis and the Effect Compartment, 315	
		16.5.1 Simulation Exercise, 318	
	Probl	lems, 319	
	Refe	rences, 321	
17	Mecl	nanism-Based Integrated Pharmacokinetic-Pharmacodynamic Models	323
	17.1	Introduction, 324	
	17.2	Alternative Models for Drug-Receptor Interaction: Operational	
		Model of Agonism, 325	
		17.2.1 Simulation Exercise, 329	
	17.3	Physiological Turnover Model and Its Characteristics, 329	
		17.3.1 Points of Drug Action, 330	
	17.4	17.3.2 System Recovery After Change in Baseline Value, 330	
	17.4		
		17.4.1 Characteristics of Indirect Effect Drug Responses, 33317.4.2 Characteristics of Indirect Effect Models Illustrated	
		Using Model I, 334	
		17.4.3 Other Indirect Models, 340	
	17.5		
		17.5.1 Simulation Exercise, 343	
	17.6		
		17.6.1 Counter-regulatory Force Model, 345	
		17.6.2 Precursor Pool Model of Tolerance, 348	
	17.7	2110000, 350	
		17.7.1 Application of the Turnover Model to Irreversible Drug	
		Action, 350	
	17.8	17.7.2 Model for Hematological Toxicity of Anticancer Drugs, 352	
	17.0	110gression Wodels, 550	
		The stag recopolition, 550	
		17.8.2 Drug Interaction with a Disease, 356	

17.8.3 Disease Progression Models, 356

Problems, 360 References, 365

Appendix	A Review of Exponents and Logarithms	368
	Exponents, 368	
A.2	Logarithms: log and ln, 369	
A.3	Performing Calculations in the Logarithmic Domain, 370	
	A.3.1 Multiplication, 370	
	A.3.2 Division, 371	
	A.3.3 Reciprocals, 371	
	A.3.4 Exponents, 371	
A.4		
	Decay Function: e^{-kt} , 373	
A.6	Growth Function: $1 - e^{kt}$, 374	
A.7	Decay Function in Pharmacokinetics, 374	
Probl	lems, 375	
Appendix	B Rates of Processes	377
B.1	Introduction, 377	
B.2	Order of a Rate Process, 378	
B.3	Zero-Order Processes, 378	
	B.3.1 Equation for Zero-Order Filling, 378	
	B.3.2 Equation for Zero-Order Emptying, 379	
	B.3.3 Time for Zero-Order Emptying to Go to 50%	
	Completion, 379	
B.4	First-Order Processes, 380	
	B.4.1 Equation for a First-Order Process, 380	
	B.4.2 Time for 50% Completion: The Half-Life, 381	
B.5	Comparison of Zero- and First-Order Processes, 382	
B.6	Detailed Example of First-Order Decay in Pharmacokinetics, 382	
	B.6.1 Equations and Semilogarithmic Plots, 382	
	B.6.2 Half-Life, 383	
	B.6.3 Fraction or Percent Completion of a First-Order Process	
	Using First-Order Elimination as an Example, 384	
B.7	Examples of the Application of First-Order Kinetics to	
	Pharmacokinetics, 385	
Appendix	C Creation of Excel Worksheets for Pharmacokinetic Analysis	387
C.1	Measurement of AUC and Clearance, 387	
	C.1.1 Trapezoidal Rule, 388	
	C.1.2 Excel Spreadsheet to Determine $AUC_{0\to\infty}$ and	
	Clearance, 389	
C.2	Analysis of Data from an Intravenous Bolus Injection in a	
	One-Compartment Model, 393	
C.3	Analysis of Data from an Intravenous Bolus Injection in a	
_	Two-Compartment Model, 394	
C.4	Analysis of Oral Data in a One-Compartment Model, 398	
C.5	Noncompartmental Analysis of Oral Data, 399	
Appendix		ons 403
D.1	Assumptions, 403	

xvi CONTENTS

	asic Equation for Plasma Concentration After Multiple ntravenous Bolus Injections, 403	
	teady-State Equations, 406	
Appendix E	Summary of the Properties of the Fictitious Drugs Used	
	in the Text	407
Appendix F	Computer Simulation Models	409
Glossary of	Abbreviations and Symbols	410
Index		415

PREFACE

The behavior and characteristics of therapeutic drugs vary enormously. For example, doses differ more than a thousandfold. Some drugs must be taken three times a day, others once daily, and some every month. The response to some therapies occurs immediately, whereas for others it may take days or even weeks for the response to be apparent. Some drugs must be taken with food; others must be taken on an empty stomach. Concurrent medications interact with some drugs but not with others. The study of pharmacokinetics (the dose—concentration relationship) and pharmacodynamics (the concentration—response relationship), which have been referred to as the pillars of clinical pharmacology, unlocks the mystery of this behavior and brings clarity to diverse patterns of drug action. The goal of this book is to provide straightforward, uncomplicated, but comprehensive coverage of the essentials of pharmacokinetics and pharmacodynamics. I hope the book will enable a large and diverse group of students to develop an interest in this subject and gain a better understanding of the properties and behaviors of drugs.

Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook and Computer Simulations is an introductory textbook suitable to accompany courses in pharmacokinetics, pharmacodynamics, and clinical pharmacology in pharmacy and medical schools. It is also directed toward people in the pharmaceutical field who want to gain an understanding of this area through self-study. The book is organized and written with several objectives in mind. First, as an introductory textbook, the intent is to present the material in as simple a way as possible, without compromising the accuracy and scope of the material. I think it is important that students not be overwhelmed during their initial exposure. Interested students can always find more advanced literature. Second, simulations are integrated into the text to allow students to visualize important concepts and to promote understanding. Pharmacokinetics and pharmacodynamics are subjects that must be approached with the goal of understanding, not memorizing, the material. The text provides exercises to guide readers through simulations, but readers are also encouraged to experiment with simulations on their own. A third goal is to balance the qualitative side of pharmacokinetics with the quantitative side, or equations. Although only a fraction